FDA approves BRAVNETSA™ (lutetium Lu 177 dotatate) for patients with SSR+ve GEP-NETs, including foregut, midgut, and hindgut NEC tumors October 1, 2026
FDA Approves WELIREG + LENVIMA for Certain Previously Treated Adult Patients With clear cell RCC October 1, 2026
